Selected discussion
Feline Vaccines: MSD Launches New RNA-Based Vaccine Range in Europe
MSD Animal Health launches six adjuvant-free feline vaccines in Europe, featuring RNA technology, 0.5 mL doses, and immunity lasting up to three years.
Six adjuvant-free vaccines featuring 0.5 mL doses and immunity lasting up to three years. Unveiled at WSAVA 2026 in Warsaw, the new range represents the first major innovation in feline vaccine technology in two decades.
Nobivac NXT® Feline, the new feline vaccine range from MSD Animal Health, is now available in Europe. The range includes six vaccines combining adjuvant-free formulations, low-volume doses (0.5 mL), and, in products containing the feline leukemia virus (FeLV) component, RNA-particle technology, introduced for the first time in a companion animal vaccine in the European Union. The launch was announced at the WSAVA 2026 Congress in Warsaw on October 12, marking the first significant advancement in feline vaccine technology in the past 20 years.
Vaccination remains a cornerstone of preventive feline medicine, yet vaccination coverage among cats remains insufficient. A…
Discussion thread
Community replies
Follow the line down to read the conversation in order.
No replies yet
No replies yet. Be the first professional to join this discussion.
Use the reply box above to start the conversation.
Join this discussion
Add your reply
Share a professional insight, ask a focused question, or add relevant clinical experience.
Member participation
Log in to join the discussion
Share an answer, ask a question, reply to another professional, or mark useful contributions as helpful.